Featured Opinions
The shame of DTC marketers (and I use the term loosely)
Social Media has overtaken porn as the #1 activity on the Web.
Change is good for others! Don't forget common sense in designing training...
Recently I visited a client who explained that their latest product launch included giving reps 2 days off the road to do 8 hours of e-learning training. Can you imagine actually doing that?
The start of the new harsher FDA
From John Mack's pharma blog forum comes this disturbing post: http://www.forums.pharma-mkting.com/showthread.php?t=19701
DTC mixed messages from patients
by Anonymous (not verified)
A recent study in the Journal of Clinical Oncology has good and bad news on the effects of DTC advertising. Researchers at the Dana Farber Cancer Institute in Boston surveyed 348 patients with various types of cancer and found that 86.2% of the three-quarters who responded were aware of...
Key account management planning
by Joanna Allen
Key account management continues to be a topic of hot debate, with Hanno last week asking the question are we doing it or just talking about it?
It should come as no surprise to anyone that once again the NY Times has run a front page article on ghostwriting journal articles on the their business section.
To outsource forecasting - or not
by Anonymous (not verified)
There was an interesting debate that took place as part of one of the roundtables at our recent Pharma Forecasting Excellence Summit that has kept me thinking ever since.
by Alan Gillies
It is an increasingly common question being asked or investigated within the majority of Pharmaceutical companies these days.The intriguing question is what is the driver behind the foc
Fixing the rep-physician relationship
by Anonymous (not verified)
Who is on, who is off the road?
What do you believe will happen, when you decide to improve your target list, leveraging the huge possibilities that externally researched lists deliver? Your representatives have decided w
Why bioscientists aren't warming to social media
by Clifford M
BioCrowd (www.biocrowd.com)co-founder, Vincent Racaniello [1], and I were chatting the other day with Crowdvine [2] [1] http://www.biocrowd.com/profiles/18035 [2] http://www.crowdvine.com/
Can we build learning organisations and create knowledge management systems in the industry?
by Joanna Allen
During the course of my MBA studies I have been drawn to the subject of building learning organisations and managing the knowledge acquired through the learning process. This led me to consid
Does re-labelling reps create account managers?
Two major questions are currently around: 1) Will there be a new sales model? 2) What will it look like? Since I tend to differentiate, it is not about a new
Help, I'm depressed and I can't get up!
by Bruce Benway
Government data released last week shows that U.S. spending on mental illness is growing at a faster pace than spending on any other health care category.
Mining Prescription Drug User Data
by Clifford M
Like most of you, I assumed that my prescription information and history was private and that only healthcare professionals were privy to it.
by Anonymous (not verified)
I'm not sure I've ever really grasped the potential importance of packaging and medication information leaflets to patient adherence.
It is time to dismantle marketing departments?
Marketing is not a department but a function that should run through the veins of any organisation.
What is Key Account Management?
by Joanna Allen
I recently read a debate on a website which asked the question what is KAM in the pharmaceutical industry?
What the new "tougher FDA" means for DTC marketing
The announcement this week from the new head of the FDA that they are going get tougher on marketing could not have come at a worse time for drug companies who are already realing from a hostile ma
Key trends in the oncology market
by Anonymous (not verified)
The demand for oncology drugs will continue to grow as healthcare systems worldwide emphasize cancer detection and treatment.